Cargando…

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Zhang, Zhuoliang, Fang, Xingliang, Xie, Guilin, Zhu, Jinlong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185902/ https://www.ncbi.nlm.nih.gov/pubmed/34113403 http://dx.doi.org/10.3892/ol.2021.12836

Ejemplares similares

GATA3 is downregulated in HCC and accelerates HCC aggressiveness by transcriptionally inhibiting slug expression
por: Zhang, Zhuoliang, et al.
Publicado: (2021)

Molecular network of HCC aggressiveness
por: Kim, Sang Geon, et al.
Publicado: (2015)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

A Liver Index and its Relationship to Indices of HCC Aggressiveness
por: Carr, Brian I, et al.
Publicado: (2016)

GATA3 is downregulated in osteosarcoma and facilitates EMT as well as migration through regulation of slug
por: Ma, Linjie, et al.
Publicado: (2018)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients
por: Lu, Feng, et al.
Publicado: (2020)

Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC
por: Wei, Yulong, et al.
Publicado: (2021)

miR-593 inhibits proliferation and invasion and promotes apoptosis in non-small cell lung cancer cells by targeting SLUG-associated signaling pathways
por: Wei, Fang, et al.
Publicado: (2022)

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]
Publicado: (2021)

LHX6 Affects Erlotinib Resistance and Migration of EGFR-Mutant Non-Small-Cell Lung Cancer HCC827 Cells Through Suppressing Wnt/β-Catenin Signaling [Corrigendum]
Publicado: (2021)

Hepatocellular carcinoma: HCC
por: Blum, Hubert E.
Publicado: (2011)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

Splenic Volume, an Easy-To-Use Predictor of HCC Late Recurrence for HCC Patients After Hepatectomy
por: Fang, Tongdi, et al.
Publicado: (2022)

HNRNPC downregulation inhibits IL‐6/STAT3‐mediated HCC metastasis by decreasing HIF1A expression
por: Liu, Danfei, et al.
Publicado: (2022)

HCC surveillance results in earlier HCC detection: results from an Indian cohort
por: Kohli, Anita, et al.
Publicado: (2014)

Inhibition of Migration, Invasion and Drug Resistance of Pancreatic Adenocarcinoma Cells – Role of Snail, Slug and Twist and Small Molecule Inhibitors [Corrigendum]
Publicado: (2022)

Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring
por: Sun, Na, et al.
Publicado: (2020)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
por: Huang, Yan, et al.
Publicado: (2022)

NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway
por: Yu, SiZhe, et al.
Publicado: (2021)

Corrigendum to: The transcription factors slug (SNAI2) and snail (SNAI1) regulate phospholipase D (PLD) promoter in opposite ways towards cancer cell invasion
Publicado: (2023)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet
por: Ganguly, Souradipta, et al.
Publicado: (2021)

CXCR2 inhibition enables NASH-HCC immunotherapy
por: Leslie, Jack, et al.
Publicado: (2022)

Aggressive primary gastric lymphoma (PGL) masquerading as hepatocellular cancer (HCC) in alcoholic cirrhosis
por: Ahmed, Moiz, et al.
Publicado: (2021)

Decision making in elderly HCC
por: Trovato, M A, et al.
Publicado: (2011)

The Epigenetic Regulation of HCC Metastasis
por: Han, Tae-Su, et al.
Publicado: (2018)

Strategies for HCC target discovery
por: Molina-Sánchez, Pedro, et al.
Publicado: (2017)

Inflammatory Mechanisms of HCC Development
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

HCC diagnosis DFP report
Publicado: (2021)

Diabetes medications and risk of HCC
por: Plaz Torres, Maria Corina, et al.
Publicado: (2022)

HCC: RNA-Sequencing in Cirrhosis
por: Wang, Haoyu, et al.
Publicado: (2023)

Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT
por: Yang, Yan, et al.
Publicado: (2019)

Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
por: Wu, Le, et al.
Publicado: (2021)

Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high‐risk chronic hepatitis B patients for HCC surveillance in Thailand
por: Rattananukrom, Chitchai, et al.
Publicado: (2022)

[Corrigendum] Lidocaine inhibits the invasion and migration of TRPV6‑expressing cancer cells by TRPV6 downregulation
por: Jiang, Yuan, et al.
Publicado: (2023)

RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo
por: Wang, Wei, et al.
Publicado: (2014)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Study on the changes of CT texture parameters before and after HCC treatment in the efficacy evaluation and survival predication of patients with HCC
por: Zhou, Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lfp30s3jioeqlqt5o5u1gsnv2r